AP Biosciences Inc
AP Biosciences Inc researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, an… Read more
AP Biosciences Inc (6945) - Total Liabilities
Latest total liabilities as of September 2025: NT$127.35 Million TWD
Based on the latest financial reports, AP Biosciences Inc (6945) has total liabilities worth NT$127.35 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AP Biosciences Inc - Total Liabilities Trend (2020–2024)
This chart illustrates how AP Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AP Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of AP Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hubei Huaqiang High-Tech Co. Ltd. A
SHG:688151
|
China | CN¥631.74 Million |
|
Sterling and Wilson Renewable Energy Limited
NSE:SWSOLAR
|
India | ₹43.99 Billion |
|
Baskent Dogalgaz Dagitim Gayrimenkul Yatirim Ortakligi AS
IS:BASGZ
|
Turkey | TL17.64 Billion |
|
Sichuan Dawn Precision Technology Co Ltd
SHE:300780
|
China | CN¥822.63 Million |
|
Australian Ethical Investment Ltd
AU:AEF
|
Australia | AU$29.28 Million |
|
ICRA Limited
NSE:ICRA
|
India | ₹2.72 Billion |
|
Huarong Chemical Co. Ltd.
SHE:301256
|
China | CN¥606.19 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down AP Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AP Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AP Biosciences Inc (2020–2024)
The table below shows the annual total liabilities of AP Biosciences Inc from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$104.38 Million | -2.13% |
| 2023-12-31 | NT$106.65 Million | +2260.04% |
| 2022-12-31 | NT$4.52 Million | -78.63% |
| 2021-12-31 | NT$21.15 Million | +230722.96% |
| 2020-12-31 | NT$9.16K | -- |